Skip to main content

Table 2 Serum creatinine concentration in different groups

From: The therapeutic potential of Camel Wharton jelly mesenchymal stem cells (CWJ-MSCs) in canine chronic kidney disease model

Creatinine

zero time

1st week

2nd week

3rd week

1st

dose of CMSCs

4th

week

5th week

2nd dose of CMSCs

6th week

8th week

10th week

12th week

G1

(CKD)

0.51 ± 0.03

0.74 ± 0.06

2.92 ± 0.09

3.14 ± 0.08

3.17 ± 0.13

3.23 ± 0.09

3.2 ± 0.11

3.23 ± 0.08

3.28 ± 0.1

3.32 ± 0.07

G2

(camel WJMSCs)

0.56 ± 0.05

0.85 ± 0.04

2.81 ± 0.04

3.22 ± 0.08

2.59 ± 0.1*

2.45 ± 0.1*

2.34 ± 0.08*

2.09 ± 0.13*

1.96 ± 0.07*

1.86 ± 0.08*

  1. Data are presented as mean value ± SE. * indicates significant difference at P value < 0.05